SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Non-Tech : NIFTY NINE IN NINETY NINE PLUS ONE -- Ignore unavailable to you. Want to Upgrade?


To: RCMac who wrote (294)1/31/1999 12:00:00 PM
From: Arthur Radley  Read Replies (3) | Respond to of 613
 
Well fellows, it looks like the bottle of wine will be heading to Mike McFarland if the trend after the first month continues:
First Months Results

Mike McFarland $143,743.58
Brad Anderson 114,827.94
DAK 108,048.52(New Kid on the Block)
RCMAC 107,725.86
Scott Davis 105,887.32
MKilloran 104,278.12
TexasDude 104,187.77
Steve Lokness 102,546.34
Harold V 101,892.65
Bald Eagle 98,008.69
Greg U 95,808.31(But Doesn't Include CFGL)

Greg, if you could give me the closing price of your Canadian stock, I will refigure the totals.

Does anyone have a data base that will allow them to track the 110 stocks represented in the various portfolios. It has taken me nearly 2 hours this morning to calculate the standings. If so, I will provide you the number of shares and beginning prices so that we can get an update much easier than my method.



To: RCMac who wrote (294)1/31/1999 1:39:00 PM
From: RCMac  Respond to of 613
 
Another perspective on CORR: Message 7578160

Excerpts:

"growth in overall market [for anti-clotting agents] should slow in 1999 with total CNTO sales of $450 million or so, up 25% or so from $360 million reported sales in 1997. CORR/MRK will likely take $50-75 million each leading to a bullish case market size of $600 million (75% CNTO, 13% MRK and 12% CORR - I have to assume MRK will hold slight lead). On a volume basis, assuming 1.5x higher Reo pricing, CNTO would have 67% share to 17% and 16% shares for MRK and CORR.."

"CORR will likely do $70 million end-user sales in 1999. This should grow to $150-200 million by 2001. Ramp is slower than expected, but from a small base, this will ultimately be good for CORR."

My horseback guess -- and he's looked at this in greater detail than I have -- is that he underestimates CORR's likely market share and overestimates CNTO's, but as a CORR shareholder I'll be happy even if he's exactly right. Notably, the author owns both CNTO and CORR.

-- RCM